SCHEMBL11889396

SCHEMBL11889396

CNc1ncc2cc(-c3c(C)ccc4c(Nc5ccc(OC)c(OC)c5)nn(C)c34)ccc2n1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.53
BRAF P15056 4/20 0.53
KDR P35968 4/20 0.50
MAPK14 Q16539 4/20 0.50
TEK Q02763 1/20 0.50
EIF2AK3 Q9NZJ5 1/20 0.47
EIF2AK4 Q9P2K8 1/20 0.47
SYK P43405 5/20 0.41
ABCG2 Q9UNQ0 3/20 0.40
BRD4 O60885 1/20 0.40
PLK1 P53350 1/20 0.38
ABCB1 P08183 1/20 0.38
ABCC1 P33527 1/20 0.38
FGFR4 P22455 3/20 0.38
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
EGFR P00533 1/20 0.37
CLK1 P49759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11889301 0.95 LCK (0.53) LCKBRAFKDRMAPK14TEK
SCHEMBL11889081 0.93 BRAF (0.55) LCKBRAFKDRMAPK14TEK
SCHEMBL11889202 0.93 BRAF (0.55) LCKBRAFKDRMAPK14TEK
SCHEMBL11889497 0.93 LCK (0.51) LCKBRAFKDRMAPK14TEK
SCHEMBL2263907 0.90 BRAF (0.60) LCKBRAFKDRMAPK14TEK
SCHEMBL11889121 0.90 LCK (0.56) LCKBRAFKDRMAPK14TEK
SCHEMBL11889057 0.89 LCK (0.58) LCKBRAFKDRMAPK14TEK
SCHEMBL11888979 0.89 LCK (0.48) LCKBRAFKDRMAPK14TEK
SCHEMBL11889296 0.88 LCK (0.53) LCKBRAFKDRMAPK14TEK
SCHEMBL11889389 0.88 LCK (0.52) LCKBRAFKDRMAPK14TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976836-B9 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2013-02-06 EP disclosed
EP-1976836-B1 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2012-08-22 EP disclosed
EP-2481729-A1 Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases Amgen Inc. (US) 2012-08-01 EP disclosed